PUBLICATION ALERT : JOURNAL OF CONTROLLED RELEASE - Pharos University in Alexandria, Egypt
Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence
In this scientific report, a scientific team from Alexandria, Egypt, studied the therapeutic potentials of orally administered Vitamin A (VA) coupled Valsartan-loaded liposomes (VLCs) in a rat model of CCL4-induced liver fibrosis. They used the PhotonIMAGERTM OPTIMA to quantify relocation of Nile Red labelled VA coupled VLCs from the intestine to the liver upon onset of fibrosis for several days by Ex vivo fluorescence imaging. Confocal microscopy examination of immunofluorescently-stained HSCs in liver sections confirmed nuclear uptake of VLCs in hepatic stellate cells, in accordance with Valsartan’s mode of action. The authors concluded that VA coupled nanocarriers represented a promising targeted delivery method for oral administration of Valsartan in antifibrotic therapy.